ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.95633
-0.16%
Brent Oil
83.455
0.40%
Bitcoin
64,252.98
0.40%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Centogene NV (CNTG)

  7. Centogene NV (CNTG) Noticias

CNTG Centogene NV

0.442851
0.00 (0.00%)
05 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Centogene NV CNTG NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 0.442851 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.442851
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/4/202415:30GLOBECENTOGENE Receives Nasdaq Non-Compliance Notice
19/3/202405:30GLOBECENTOGENE Extends Strategic Partnership With Takeda to..
29/2/202416:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/2/202416:00GLOBECENTOGENE Collaborates on Research Published in Science..
28/2/202405:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202405:30GLOBECENTOGENE Announces Receipt of Nasdaq Notice of Delisting..
28/2/202405:30GLOBECENTOGENE Explores Strategic Alternatives
28/2/202405:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/1/202405:30GLOBECENTOGENE and the Laboratory of Human Genetics of Infectious..
25/1/202405:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/1/202405:30GLOBECENTOGENE Receives French Research Tax Credit Accreditation
24/1/202405:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/1/202405:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/1/202405:30GLOBECENTOGENE and The Michael J. Fox Foundation Announce..
18/1/202406:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/1/202405:30GLOBECENTOGENE Announces Preliminary Full Year 2023 Revenue
19/12/202306:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/12/202305:30GLOBECENTOGENE Announces Voting Results of Extraordinary General..
18/12/202305:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202305:33EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202305:30GLOBECENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study,..
01/12/202305:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202305:30GLOBECENTOGENE and Lifera, a Public Investment Fund (PIF)..
28/11/202305:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202307:30GLOBECENTOGENE, University College London, and Global Team of..
03/11/202315:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/10/202306:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/10/202305:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/10/202305:30GLOBECENTOGENE Expands Multiomic Diagnostic Portfolio With..
06/10/202315:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202307:30GLOBECENTOGENE to Present at H.C. Wainwright 25th Annual Global..
07/9/202316:00GLOBECENTOGENE Reports First Half 2023 Financial Results
07/9/202316:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/9/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/9/202307:00GLOBECENTOGENE Announces Publication Establishing Lyso-Gb1 as a..
31/8/202315:30GLOBECENTOGENE Receives Nasdaq Non-Compliance Notification..
31/8/202315:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/8/202315:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/8/202305:30GLOBECENTOGENE to Participate in Upcoming Conferences in August
14/7/202305:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/7/202305:30GLOBECENTOGENE Regains Compliance With Nasdaq Listing..
12/7/202306:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/7/202306:30GLOBECENTOGENE Biodatabank Reveals Unique Genetic Variants in..
02/7/202304:00PRNUSLifera and CENTOGENE, Enter Strategic Collaboration -..
30/6/202315:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/6/202315:30GLOBECENTOGENE Announces Approval of All Resolutions Tabled at..
27/6/202306:30GLOBECENTOGENE and Lifera, a Biopharma Company Owned by the PIF,..
14/6/202315:30GLOBECENTOGENE Receives Nasdaq Notification Regarding Minimum..
16/5/202317:25GLOBECENTOGENE Reports Full Year 2022 Financial Results

Su Consulta Reciente

NASDAQ
CNTG
Centogene NV
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados